Targeted expression of receptor-associated late transducer inhibits maladaptive hypertrophy via blocking epidermal growth factor receptor signaling

Hypertension

Volumn 53, Issue 3, 2009, Pages 539-548

  Cai, Jun ^a,b   Yi, Fang Fang ^b   Yang, Long ^b   Shen, Di Fei ^c,d   Yang, Qinling ^e   Li, Ankang ^f   Ghosh, Asish K ^g   Bian, Zhou Yan ^c,d   Yan, Ling ^c,d   Tang, Qi Zhu ^c,d   Li, Hongliang ^c,d   Yang, Xin Chun ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c WUHAN UNIVERSITY   (China)

^d RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cardiac hypertrophy; EGFR; ERK1 2; Fibrosis; Heart failure; RALT

Indexed keywords

COLLAGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN RALT; UNCLASSIFIED DRUG; ANGIOTENSIN II; ISOPRENALINE; RALT PROTEIN, MOUSE; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HEART FUNCTION; HEART HYPERTROPHY; HEART MUSCLE CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ADENOVIRUS; ANIMAL; C57BL MOUSE; CARDIOMEGALY; CELL CULTURE; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DISEASE MODEL; ECHOCARDIOGRAPHY; FIBROSIS; GENETICS; HEART MUSCLE; MALE; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE;

ADENOVIRIDAE; ANGIOTENSIN II; ANIMALS; CARDIOMEGALY; CELLS, CULTURED; COLLAGEN; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; FIBROSIS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOPROTERENOL; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCARDIUM; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 61749100068     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.120816     Document Type: Article

References (29)

1. Dorn GW II. The fuzzy logic of physiological cardiac hypertrophy. Hypertension. 2007;49:962-970.
2. Reudelhuber TL, Bernstein KE, Delafontaine P. Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look. Hypertension. 2007;49:1196-1201.
3. Epstein JA, Parmacek MS. Recent advances in cardiac development with therapeutic implications for adult cardiovascular disease. Circulation. 2005;112:592-597.
4. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004;109:1580-1589.
5. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signaling pathways. Nat Rev Mol Cell Biol. 2006;7:589-600.
6. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol. 2007;292:C82-C97.
7. Zhai P, Galeotti J, Liu J, Holle E, Yu X, Wagner T, Sadoshima J. An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy. Circ Res. 2006;99:528-536.
8. Kagiyama S, Eguchi S, Frank GD, Inagami T, Zhang YC, Phillips MI. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation. 2002;106:909-912.
9. Kagiyama S, Qian K, Kagiyama T, Phillips MI. Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy. Hypertension. 2003;41:824-829.
10. Ferby I, Reschke M, Kudlacek O, Knyazev P, Pantè G, Amann K, Sommergruber W, Kraut N, Ullrich A, Fässler R, Klein R. Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med. 2006;12:568-573.
11. Xu D, Makkinje A, Kyriakis JM. Gene 33 is an endogenous inhibitor of epidermal growth factor (EGF) receptor signaling and mediates dexamethasone-induced suppression of EGF function. J Biol Chem. 2005;280: 2924-2933.
12. Xu D, Patten RD, Force T, Kyriakis JM. Gene 33/RALT is induced by hypoxia in cardiac myocytes, where it promotes cell death by suppressing phosphatidylinositol 3-kinase and extracellular signal-regulated kinase survival signaling. Mol Cell Biol. 2006;26:5043-5054.
13. Li HL, She ZG, Li TB, Wang AB, Yang Q, Wei YS, Wang YG, Liu DP. Overexpression of myofibrillogenesis regulator-1 aggravates cardiac hypertrophy induced by angiotensin II in mice. Hypertension. 2007;49: 1399-1408.
14. Dubey RK, Gillespie DG, Jackson EK. Adenosine inhibits collagen and protein synthesis in cardiac fibroblasts: role of A2B receptors. Hypertension. 1998;31:943-948.
15. Li HL, Huang Y, Zhang CN, Liu G, Wei YS, Wang AB, Liu YQ, Hui RT, Wei C, Williams GM, Liu DP, Liang CC. Epigallocathechin-3 gallate inhibits cardiac hypertrophy through blocking reactive oxidative species-dependent and -independent signal pathways. Free Radical Biol Med. 2006;40:1756-1775.
16. Shah BH, Catt KJ. Matrix metalloproteinase-dependent EGF receptor activation in hypertension and left ventricular hypertrophy. Trends Endocrinol Metab. 2004;15:241-243.
17. Shah BH, Catt KJ. A central role of EGF receptor transactivation in angiotensin II-induced cardiac hypertrophy. Trends Pharmacol Sci. 2003;24:239-244.
18. Piiper A, Zeuzem S. Receptor tyrosine kinases are signaling intermediates of G-protein-coupled receptors. Curr Pharm Des. 2004;10:3539-3545.
19. Takashima S. Pharmacological role of HB-EGF shedding by angiotensin II in cardiac myocytes. Nippon Yakurigaku Zasshi. 2004;124:69-75.
20. Fiorentino L, Pertica C, Fiorini M, Talora C, Crescenzi M, Castellani L, Alemà S, Benedetti P, Segatto O. Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain. Mol Cell Biol. 2000;20: 7735-7750.
21. Fiorini M, Ballarò C, Sala G, Falcone G, Alemà S, Segatto O. Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control. Oncogene. 2002; 21:6530-6539.
22. Iwamoto R, Yamazaki S, Asakura M, Takashima S, Hasuwa H, Miyado K, Adachi S, Kitakaze M, Hashimoto K, Raab G, Nanba D, Higashiyama S, Hori M, Klagsbrun M, Mekada E. Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci U S A. 2003;100:3221-3226.
23. Chen B, Bronson RT, Klaman LD, Hampton TG, Wang JF, Green PJ, Magnuson T, Douglas PS, Morgan JP, Neel BG. Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat Genet. 2000;24:296-299.
24. Chen CH, Cheng TH, Lin H, Shih NL, Chen YL, Chen YS, Cheng CF, Lian WS, Meng TC, Chiu WT, Chen JJ. Reactive oxygen species generation is involved in epidermal growth factor receptor transactivation through the transient oxidization of Src homology 2-containing tyrosine phosphatase in endothelin-1 signaling pathway in rat cardiac fibroblasts. Mol Pharmacol. 2006;69:1347-1355.
25. Hardie WD, Davidson C, Ikegami M, Leikauf GD, Le Cras TD, Prestridge A, Whitsett JA, Korfhagen TR. EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis. Am J Physiol. 2008;294:L1217-L1225.
26. Li HL, Zhuo ML, Wang D, Wang AB, Cai H, Sun LH, Yang Q, Huang Y, Wei YS, Liu PP, Liu DP, Liang CC. Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation. 2007;115: 1885-1894.
27. Muslin AJ. MAPK signaling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci. 2008;115: 203-218.
28. Li HH, Willis MS, Lockyer P, Miller N, McDonough H, Glass DJ, Patterson C. Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins. J Clin Invest. 2007;117:3211-3223.
29. Sugden PH. Signaling pathways in cardiac myocyte hypertrophy. Ann Med. 2001;33:611-622.